Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Xavier Llor MD, PhD

Xavier Llor MD, PhD

Associate Professor; Medical Director, Colorectal Cancer Prevention Program; Co-Director of Cancer Genetics and Prevention Program, Yale University School of Medicine, New Haven, Connecticut

Dr. Xavier Llor obtained his MD degree at the Autonomous University of Barcelona and his PhD in molecular biology at the University of Barcelona. He completed his Internal Medicine Residency at the University of Chicago-Lutheran General Hospital Program and his GI fellowship at the University of Illinois at Chicago. In 2014, Dr. Llor joined Yale University to become co-Director of the Cancer Genetics and Prevention Program at Yale’s Cancer Center, and Medical Director of the Colorectal Cancer Prevention Program. In January 2020 he was been appointed Associate Director for Cancer Screening, Community Engagement and Health Equity at Yale’s Cancer Center.

A clinically active gastroenterologist, Dr. Llor’s research and clinical interests relate to colorectal cancer with an emphasis on genetics and disparities. He spearheaded and carried out three large prospective cohorts of colorectal cancer patients and controls. The first two, Epicolon I and II, were nationwide population-based studies in Spain that have produced over 50 peer-reviewed publications mostly addressing genetic factors implicated in CRC development. The most recent cohort, the Chicago Colorectal Cancer Consortium, was designed to address the influence of genetic and environmental factors on colorectal cancer disparities and has already resulted in a number of manuscripts, some still in preparation. Some important contributions from Dr. Llor’s lab include the description of the best diagnostic approaches to Lynch syndrome diagnosis; clinical and molecular characterization of mismatch repair proficient hereditary non-polyposis colorectal cancer (type X); identification of distinct clinical and molecular features of colorectal cancers in young African Americans.

Dr. Llor has been involved in national scientific organizations for years. He is currently a member of the Steering Committee of the National Colorectal Cancer Roundtable, where he represents the American Gastroenterological Association (AGA), and member of the National Comprehensive Cancer Network guidelines committee on High risk/Inherited colorectal cancer and Colorectal Cancer Screening.